Targeting the mutant IDH1/2 has opened a novel therapeutic avenue for ICC patients with IDH1 mutations, and the FDA have approved the mutant IDH1 inhibitor ivosidenib for treating IDH1-mutated advanced cholangiocarcinoma. Here, IDH1 is linked to cholangiocarcinoma.